Dear Ms. Chianese:

Please refer to your supplemental new drug applications, dated and received on November 30, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

<table>
<thead>
<tr>
<th>NDA Number</th>
<th>Supplement Number</th>
<th>Drug Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-634</td>
<td>042</td>
<td>Levaquin® (levofloxacin) Tablets, 250 mg, 500 mg, and 750 mg</td>
</tr>
<tr>
<td>20-635</td>
<td>045</td>
<td>Levaquin® (levofloxacin) Injection and Levaquin® (levofloxacin in 5% dextrose) Injection, 5 mg/mL</td>
</tr>
<tr>
<td>21-721</td>
<td>010</td>
<td>Levaquin® (levofloxacin) Oral Solution, 25 mg/mL</td>
</tr>
</tbody>
</table>

We acknowledge receipt of your submissions dated May 15, 2007.

These “Changes Being Effected” supplemental new drug applications provide for the following revision (strikethrough = deleted and double-underlined = added) of the ADVERSE REACTIONS/Post-Marketing Adverse Reactions subsection of the patient package insert for Levaquin® to add new adverse reactions and reorganize the existing list of adverse reactions:

Additional adverse events reported from worldwide post-marketing experience with levofloxacin include: allergic pneumonitis; **hypersensitivity reactions sometimes fatal**, including anaphylactic shock, anaphylactoid reaction, serum sickness, angioneurotic edema; dysphonia, abnormal EEG; encephalopathy; eosinophilia, erythema multiforme; Stevens-Johnson Syndrome; toxic epidermal necrolysis; peripheral neuropathy; rhabdomyolysis; muscle injury including rupture; tendon rupture; electrocardiogram QT prolonged; torsades de pointes; vasodilation; psychosis; paranoia; isolated reports of suicide attempts or suicidal ideation; multi-system organ failure; pseudomembranous/C. difficile colitis; hepatitis; anosmia; ageusia;
hypoacusis; dysphonia, vision disturbances including diplopia, visual acuity reduced, vision blurred, scotomata; leukocytoclastic vasculitis; photosensitivity reaction; acute renal failure; interstitial nephritis; eosinophilia; hemolytic anemia; leukopenia; pancytopenia; aplastic anemia; increased International Normalized Ratio (INR)/prothrombin time.

We have completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon text for the package insert.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical in content to the enclosed labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission “SPL for approved NDA 20-634/S-042, NDA 20-635/S-045, NDA 21-721/S-010.”

If you issue a letter communicating important information about these drug products (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to these NDAs and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rebecca D. Saville, Pharm.D., Regulatory Project Manager, at (301) 796-1600.

Sincerely,

{See appended electronic signature page}

Renata Albrecht, M.D.
Director
Division of Special Pathogen and Transplant Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Renata Albrecht
5/31/2007 09:15:08 AM